• VOD-new-1
  • linkedin
Friday, 06 September 2013 09:44

Abstract: Evaluation of the In Vitro Human Trunk Skin Percutaneous Absorption of Active Substances Incorporated Simultaneously in Lipoderm and Lipoderm ActiveMax

This Abstract Poster Presentation presented at PAINWeek 2013 (4 - 7 Sep 2013) in Las Vegas, Nevada deals with evaluation of the in vitro human trunk skin percutaneous absorption of Ketamine HCl, Gabapentin, Clonidine HCl and Baclofen using the Franz Skin Finite Dose Model

Introduction:

The in vitro human trunk skin percutaneous absorption of transdermal compounded formulations containing four active substances – Ketamine HCl, Gabapentin, Clonidine HCl and Baclofen – incorporated simultaneously in Lipoderm and also in Lipoderm ActiveMax, was evaluated using the Franz Skin Finite Dose Model. The Franz Skin Finite Dose Model was selected to evaluate the total absorption, rate of absorption and the skin content of the four active substances simultaneously applied to the outer surface of the skin.

Read the complete abstract, and view the poster.

Click to learn more about Lipoderm.